Showing posts with label current. Show all posts
Showing posts with label current. Show all posts

Friday, September 20, 2013

0 Allergen immunotherapy as a drug: the new deal of grass allergen tablets from clinical trials to current practice







Allergen immunotherapy as a drug: the new deal of grass allergen tablets fromclinical trials to current practice



G. Manzotti, C. Lombardi



Abstract



Currently, sublingual immunotherapy (SLIT) may be performed by a number of allergen extract in different preparations but in a near future only products fulfilling the requirements from the regulatory agencies, that make mandatory a pharmaceutical quality, will be authorized. Indeed, two products with such characteristics are already available for SLIT in grass pollen allergic patients, Grazax® from Alk-Abellò and Oralair® from Stallergenes. The data from registrative trials as well as from postmarketing studies provide evidence of efficacy and safety of such products. This articles reviews the similarities and the differences of Grazax® and Oralair®, both designed as drugs for the treatment of grass pollen allergy with the aim, which is exclusive of allergen immunotherapy, to work on the natural history of allergy and not only on symptoms as rescue medications do. The aim of this paper is to evaluate the available trials with Grazax® and Oralair® in terms of pre-seasonal schedule approach to support their use in clinical practice.Such kind of treatment makes possible a continuous dialogue between clinical investigators and clinical practitioners, and is the only way for scientific progress that puts the patient’s health at the first place.



Keywords



Sublingual allergen-specific immunotherapy, grass tablets


Full Text: PDF 


Wednesday, September 11, 2013

0 Anisakis simplex: current knowledge


Anisakis simplex: current knowledge



V. Pravettoni, L. Primavesi, M. Piantanida







European Annals of Allergy and Clinical Immunology







Abstract



Anisakiasis, firstly described in 1960s in the Netherlands, is a fish-borne parasitic disease caused by the consumption of raw or undercooked fish or cephalopods contaminated by third stage (L3) larvae of the Anisakidae family, in particular Anisakis simplex (As),A. pegreffii and Pseudoterranova decipiens. Every year, approximately 20,000 cases of anisakiasis were reported worldwide, over 90% are from Japan and most others in Spain, the Netherlands and Germany, depending on the habits of fish consuming. Live As larvae can elicit i) a parasitic infection of the digestive tract or, occasionally, other organs, causing erosive and/or haemorrhagic lesions, ascites, perforations until granulomas and masses, if larva is not removed; and ii) allergic reactions, as anaphylaxis, acute/chronic urticaria and angioedema. Like other parasite infestations, As larva induces an immune adaptive response characterised by T-lymphocyte proliferation with polyclonal and monoclonal (responsible for As allergic symptoms) IgE production, eosinophilia and mastocytosis. Several As allergens, many of which thermostable, were described. In particular the major allergen Ani s 1 and Ani s 7 could characterized a past or a recent infection. There is a general agreement that an active infection is required to initiate allergic sensitivity to Anisakis. Until now, the only effective treatment for anisakiasis is the endoscopic removal of live larvae and the best protection against anisakiasis is to educate consumers about the dangers of eating raw fish and to recommend avoiding the consumption of raw or inadequately thermally treated marine fish or cephalopods.



Keywords



Anisakis simplex, anisakiasis, anisakis allergens, freezing, anaphylaxis, fish parasitic disease, adaptive immune response, lyophilized larvae challenge.


Full Text: PDFÂ